Pharma major Lupin Ltd on Thursday reported an 87.7 per cent jump in consolidated profit after tax to ₹1,468.7 crore in the fourth quarter ended March 31, mainly driven by strong performance in the US market.
The company had posted a consolidated profit after tax (PAT) of ₹782.4 crore in the corresponding quarter of the preceding fiscal, Lupin Ltd said in a regulatory filing.
Its consolidated sales in the fourth quarter rose 32.9 per cent to ₹7,391.9 crore against ₹5,562.2 crore in the year-ago period, it added.
US sales for Q4 FY2026 jumped 56.9 per cent to ₹3,398.7 crore compared to ₹2,166.6 crore in Q4 FY2025.
India sales climbed 11.5 per cent to ₹1,908.2 crore in Q4 from ₹1,711.3 crore a year ago.
For FY26, consolidated PAT surged 62 per cent to ₹5,355.5 crore against ₹3,306.3 crore in FY25.
Its consolidated sales for FY26 increased 23.9 per cent to ₹27,487.5 crore from ₹22,192.1 crore in FY25, the company said.
“Our fourth quarter and full-year results underscore the strength and resilience of our business across key geographies, with the US and India delivering strong sales growth and margin expansion,” Lupin Ltd Managing Director Nilesh Gupta said.
Building on this momentum, he said, “We are well-positioned to accelerate performance through strategic investments in technology, disciplined execution, and operational efficiencies, driving sustainable and profitable growth”.
The company’s board has recommended a dividend of ₹18 per equity share of the face value of ₹2 each for the financial year ended March 31, 2026, subject to shareholders’ approval at the ensuing annual general meeting, Lupin said.